Sign In
Last checked at 
8 Oct 2013 07:00
8 October 2013
ValiRx Plc
("ValiRx", "the Company" or "the Group")
Directorate changes
ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and personalised therapeutic development announces the following board changes:
Appointment of Mr Seppo Olavi Mäkinen as a Non-Executive Director of the Company
Seppo Mäkinen has more than 25 years of senior advisory and executive experience in board level strategic leadership and venture capital management on life science. His career includes ten years as director in Life Sciences at Sitra (Finnish Government Fund), followed by thirteen years as co-founder and Managing Partner in Bio Fund Management Oy. In 2010, Seppo founded Taikon Advisor Oy, a Finnish management consultancy firm focusing on advising and investing in life sciences ventures.
The following disclosure on Mr Seppo Olavi Mäkinen has been made pursuant to Schedule 2(g) of the AIM Rules for Companies.
Seppo Olavi Mäkinen (age 61)
Companies where he is currently a director or partner
| Companies where he has served as a director or a partner in the past 5 years |
Balonco GmbH1 | Bio Fund Management A/S3 |
Med Group Oy2 | RSP Systems A/S3 |
Taikon Advisor Oy2 | Egalet A/S3 |
ArcDia International Oy2 | |
Global Innovation Network Oy2 | |
Magnasense Technologies Oy2 | |
1Incorporated in Switzerland
2Incorporated in Finland
3 Incorporated in Denmark
Resignation of Nicholas Thorniley, Non-Executive Chairman
Mr Nicholas Thorniley has decided to leave ValiRx after over six years with the Company to pursue other opportunities and accordingly he resigned as Non-Executive Chairman on 4 October 2013.
Oliver de Giorgio-Miller, a Non-Executive Director of the Company, has been appointed Non Executive Chairman with immediate effect.
Dr Satu Vainikka, Chief Executive of ValiRx, commented: "Nick has decided that after over six years with the Company and following a successful career in the City he now wishes to leave ValiRx to pursue other opportunities. The Board and I would like to thank Nick for his contribution and wise counsel over many years and we wish him well for the future. I and all at ValiRx would also like to welcome Seppo to the board and we look forward to benefitting from his experience and working with him."
ValiRx plc Dr Satu Vainikka | Tel: +44 (0) 20 3008 4416 www.ValiRx.com
|
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Avi Robinson
| Tel:+44 (0) 20 7148 7900 |
Hybridan LLP (Broker) Claire Louise Noyce / William Lynne
| Tel: +44 (0) 20 7947 4350 / 4361 |
Peckwater PR
| Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
Notes for Editors
ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Company operates through the following divisional companies:
1. ValiFinn is the biomarkers and diagnostic development division
2. ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.
Follow the stocks
